Search clinical trials for: MLN1202 Placebo

Total 53488 results

Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis

Ulcerative Colitis
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease (GEMINI II)

Crohn's Disease

United States, Canada, Puerto Rico
Takeda

Withdrawn

Phase 1 Single Subcutaneous Dose Study of MLN1202

Healthy Japanese and Caucasian Male Adults

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease (GEMINI III)

Crohn's Disease

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis (GEMINI I)

Ulcerative Colitis

United States, Canada, Puerto Rico
Millennium Pharmaceuticals, Inc.

Completed

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

Multiple Sclerosis
Millennium Pharmaceuticals, Inc.

Completed

Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease

Atherosclerosis
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients

Crohn's Disease
Takeda

Withdrawn

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

Diabetic Nephropathy
Takeda

Withdrawn

Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease
Millennium Pharmaceuticals, Inc.

Completed

Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Crohn's Disease | Ulcerative Colitis

Canada
Millennium Pharmaceuticals, Inc.

Completed

Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab

Inflammatory Bowel Disease

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Hematopoietic Stem Cells

United States, Spain, Taiwan, Australia, Canada, Singapore, Korea, Republic of, Mexico, Switzerland, Japan, Germany, Norway, Israel, Russian Federation, Hungary, United Kingdom, Italy, Romania, Brazil, France, Austria, Belgium, Port... and more
Takeda

Withdrawn

Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease

Primary Sclerosing Cholangitis | Inflammatory Bowel Disease
Takeda

Completed

Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

Crohn's Disease

Japan
Takeda

Completed

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Ulcerative Colitis

Japan
Bavarian Nordic

Completed

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

HIV Infections

United States
Takeda

Completed

Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)

Crohn's Disease

Spain, United Kingdom, Canada, United States, Netherlands, France, Italy
Takeda

Completed

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease (GEMINI LTS)

Crohn's Disease | Ulcerative Colitis

Belgium, United States, Korea, Republic of, Malaysia, Canada, Israel, Australia, Hungary, Czechia, Germany
Takeda

Completed

Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease

Crohn's Disease

United States, Italy, Poland, France, Belgium, Canada, Hungary, Czechia
Takeda

Completed

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Colitis, Ulcerative

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Allogeneic Hematopoietic Stem Cell Transplantation

United States, Belgium, Sweden, France, Norway
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0916, MLN1202 in Treating Patients With Bone Metastases

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer

United States
Takeda

Terminated

Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

Crohn Disease | Colitis, Ulcerative

Korea, Republic of, Italy, India, Malaysia, Hungary, Serbia, Latvia, Australia, Estonia, Poland, South Africa, Czechia, Turkey, Bulgaria, New Zealand, Romania, Russian Federation, Ukraine
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Israel, United States, Hungary, Belgium, France, Poland, Ukraine, United Kingdom
Takeda

Completed

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis (ENTERPRET)

Colitis, Ulcerative

United States, Canada
Takeda

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Colitis, Ulcerative

United States, Israel, Canada, Italy, United Kingdom, Hungary, Japan, Australia, China, Greece, Belgium, Croatia, Korea, Republic of, Poland, Czechia
Takeda
Takeda Development Center Americas, Inc.

Completed

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Israel, United States, Hungary, Belgium, Canada, United Kingdom, Germany, Netherlands, Poland, Ukraine, France
Takeda

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Crohn's Disease (CD)

United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
Takeda

Completed

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Healthy Volunteers

United States
Takeda

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's Disease | Ulcerative Colitis

Belgium, Australia, Israel, United States, Hungary, Korea, Republic of, China, Canada, Croatia, Italy, Poland, Slovakia, United Kingdom, Japan, Greece
Takeda

Not yet recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease (VICTRIVA)

Crohn's Disease
Takeda

Withdrawn

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis
Millennium Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Melanoma

United States
Takeda

Not yet recruiting

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Crohn's Disease | Ulcerative Colitis
Bristol-Myers Squibb

Completed

A Study of BMS-986195 in Healthy Male Subjects

Rheumatoid Arthritis

Netherlands
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Takeda

Completed

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis (EARNEST)

Pouchitis

United States, Spain, United Kingdom, Canada, Germany, Netherlands, Italy, Belgium, France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Malignant Solid Neoplasm | Melanoma | Colitis | Lung Non-Small Cell Carcinoma | Malignant Genitourinary System Neoplasm

United States
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Chinese University of Hong Kong

Recruiting

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

COVID-19

Hong Kong
National University of Malaysia
Malaysia Palm Oil Board

Unknown

Supplementation of Oil Palm Phenolics to Healthy Participants (SPIRAL)

Cardiovascular Diseases | Hypercholesterolemia | Hyperlipidemias

Malaysia
Gladwin, Mark, MD
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age (Nitrite)

Sedentary Lifestyle | Frailty | Aging

United States
Mersin University

Completed

The Effect of Post-Cesarean Section Acupressure on the Severity of Pain and First Mobilization Distance (Acupress)

Pain | Mobilization

Turkey
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Active, not recruiting

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)

Critical Limb Ischemia

Poland
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)

Heart Failure

Poland

Search clinical trials for: MLN1202 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations